We take an open, honest and transparent approach to how we work together.
Three guiding principles shape how we work
Clarity
Flexibility
We commit to doing the right thing, reacting to the changes as they happen, and delivering what is needed – not only what is asked for.
Value
We focus on addressing your most difficult challenges – shaping your thinking and guiding your actions.
We balance client focus with technical expertise
We wrap a dedicated, multi-disciplinary team around each of our clients – allowing them to speak your language, share in your strategic priorities and foresee the next wave of challenges before they arrive.
To deliver the innovative solutions needed, these teams are supported by technical pillars of expertise:
Evidence & Value
Helping to navigate healthcare systems to maximise the value and impact of assets
Example solutions: Landscaping & decision driver analyses / Value proposition strategy / Payer evidence design & planning, including scientific advice / Pricing research
Stakeholder Engagement
Managing stakeholder engagement to maximise patient access to healthcare innovation
Example solutions: Stakeholder engagement strategy / Stakeholder mapping / Stakeholder insight gathering (e.g., expert advisory boards, surveys & interviews) / Stakeholder engagement tools
Organisational Strategy & Design
Helping to optimise biopharma teams in order to maximise the value of portfolios
Example solutions: Strategic planning frameworks / Process development & implementation support / Organisational redesign / Change management
Value Modelling & Analytics
Demonstrating value through analytical insights and economic modelling
Example solutions: Economic models / Biostatistical analysis / Observational studies / Utility estimation
Evidence Synthesis & Communication
Collating evidence and building approaches to clear communication that demonstrates the value of portfolios
Example solutions: Evidence reviews / Literature reviews / Global and local value dossiers / Access policy / Launch materials / Health technology assessment
Our thinking
The best way to understand what we can do, is to understand how we think.
Below are our recent thought leadership articles, discussing some of the recent challenges facing our industry. Contact us if you would like to discuss any of these topics, or how we could support your specific challenges.
Select Publications
The meaning of Wickenstones
Combining innovation with real-world pragmatism, we tackle our client’s most challenging issues – focusing on the whole of the problem, not just a small part.
1
We ground our approaches and solutions in common sense and pragmaticism.
2
We gain and maintain internal alignment to strengthen implementation.
3
We apply fresh thinking to each new question or challenge we are faced with – never re-heating old ideas.
Wickenstones
Old English place name for a location where a rowan tree grows from a harsh and seemingly barren stone plateau.
The persistence of this tree to overcome the savage nature of its environment and to anchor itself deep into the crevasses within the rock represents the nature of our business – grounded in evidence and dedicated to overcoming the challenges that the environment presents us with.
The senior team at the heart of your projects
Eddie has over 30 years’ experience working across multiple geographies and senior roles within the industry. He has personally led several major European launches and the creation and implementation of global access plans in a wide range of therapy areas including oncology, haematology, virology, neuroscience, cardiovascular disease and diabetes. This has included leadership of several HTA submissions to NICE, the SMC and AWMSG across a diverse set of therapy areas as well as serving on the ABPI representation to both the SMC and NICE.
Kimberley has worked with Wickenstones for over 3 1/2 years in positions of increasing responsibility.
Kimberley holds a BSC in Biomedical Sciences from the University of Edinburgh. She has broad experience as a market access consultant, having lead a broad range of projects including payer evidence and value strategy, stakeholder engagement, value modelling, evidence synthesis and communication projects
Kimberley holds a BSC in Biomedical Sciences from the University of Edinburgh. She has broad experience as a market access consultant, having lead a broad range of projects including payer evidence and value strategy, stakeholder engagement, value modelling, evidence synthesis and communication projects
Anne has nearly a decade of experience in healthcare research and strategy, with expertise in value assessment frameworks, literature reviews, primary market research, HEOR planning, and clinical and patient-reported outcomes assessment. In her current role, she is focused on addressing clients’ specific business needs and delivering high-quality deliverables which guide clinical development programs and pricing decisions, with experience across a range of therapeutic areas, including immunology, gastroenterology, neuroscience, and rare diseases. Anne holds a master’s degree in political science from Northeastern University in Boston, MA USA.
Dingeman holds a masters' in international health management from Imperial College London. He is a principle with over 10 years of experience in market access & strategy, developing plans and solutions to support the development and launch of pharmaceutical assets. His experience includes clinical and payer advisory boards, HTA submissions (inc. PAS schemes), objection handlers, value proposition development, stakeholder engagement strategies, systematic literature reviews, brand management, organisational redesign, healthcare system landscaping, surveys inc. BoI studies, RWE and pricing research. Therapy areas include diabetes, obesity, NASH, oncology, neuromuscular disorders, cystic fibrosis, epilepsy and rare diseases such as SMA, XLH, SCD and OI.
Alice as been with Wickenstones for over 4 years in positions of increasing responsibility.
Alice has an MBiochem in molecular and cellular biochemistry from St. Anne’s College, University of Oxford. In her final year she specialised in clinical and applied immunology and virology and wrote her dissertation on treatments for multiple myeloma. She has experience in researching and analysing emerging trends in the pharmaceutical and biotechnology industries. Since joining Wickenstones she has been involved in real world evidence research, market research and development of patient care pathways.
Alice has an MBiochem in molecular and cellular biochemistry from St. Anne’s College, University of Oxford. In her final year she specialised in clinical and applied immunology and virology and wrote her dissertation on treatments for multiple myeloma. She has experience in researching and analysing emerging trends in the pharmaceutical and biotechnology industries. Since joining Wickenstones she has been involved in real world evidence research, market research and development of patient care pathways.
Alysia holds a PhD in genetics, and has over 10 years’ experience delivering market access, HEOR and communication projects for clients across the life sciences industry. As our Technical Lead for Market access, Medical & Policy Communications, Alysia brings deep expertise and know-how with respect to medical writing, communication strategy and literature reviews. Alysia has experience across a range of therapeutic areas, including orphan diseases, oncology, respiratory disease, neurodegenerative disease, metabolic disease, gene therapy and regenerative medicine.
James holds a PhD in investigative medicine from Imperial College London, and has over 17 years’ experience working on and managing healthcare and strategic market access projects. This experience includes managing landscape assessments, literature reviews, value propositions, health economic models, pricing strategy, real-world evidence, advisory panels, publications and stakeholder engagement strategy. James has experience across a range of therapeutic areas, including infectious diseases, rheumatology, gastroenterology, cardiovascular disease, metabolic disease, women's health, oncology and orphan indications.